Skip to main content

Table 2 PHD1, PHD2 and PHD3 expression before and after treatment in matched cases

From: The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

  

Before n(%)

After n(%)

P value

PHD1

Overall (n = 130)

   
 

   0

87 (66.9)

19 (14.6)

0.0000

 

   1

39 (30.0)

68 (53.3)

 
 

   2

3 (2.3)

36 (27.7)

 
 

   3

1 (0.8)

7 (5.4)

 
 

EPI (n = 64)

   
 

   0

40 (62.5)

8 (12.5)

0.0000

 

   1

23 (35.9)

32 (50.0)

 
 

   2

1 (1.6)

23 (35.9)

 
 

   3

 

1 (1.6)

 
 

EPI-TAM (n = 66)

   
 

   0

47 (71.2)

11 (16.7)

0.0000

 

   1

16 (24.2)

36 (54.5)

 
 

   2

2 (3.0)

13 (19.7)

 
 

   3

1 (1.5)

6 (9.1)

 

PHD2

Overall (n = 111)

   
 

   0

62 (55.9%)

13 (11.7%)

0.0000

 

   1

31 (27.9%)

15 (13.6%)

 
 

   2

16 (14.4%)

43 (38.7%)

 
 

   3

2 (1.8%)

40 (36.0%)

 
 

EPI (n = 59)

   
 

   0

31 (52.5)

5 (8.5)

0.0000

 

   1

16 (27.1)

6 (10.2)

 
 

   2

10 (16.9)

22 (37.3)

 
 

   3

2 (3.4)

26 (44.1)

 
 

EPI-TAM (n = 52)

   
 

   0

31 (59.6)

8 (15.4)

0.0000

 

   1

15 (28.8)

9 (17.3)

 
 

   2

6 (11.5)

21(40.4)

 
 

   3

0

14 (26.9)

 

PHD3

Overall (n = 127)

   
 

   0

69/127 (54.3%)

8/127 (6.3%)

0.00

 

   1

46/127 (36.2%)

47/127 (37.0%)

 
 

   2

12/127 (9.4%)

47/127 (37.0%)

 
 

   3

0.00

25/127 (19.7%)

 
 

EPI (n = 63)

   
 

   0

29/63(46.0%)

3/63(4.8%)

0.00

 

   1

27/63 (42.8%)

22/63 (34.9%)

 
 

   2

7/63 (11.1%)

23/63 (36.5%)

 
 

   3

0.00

15/63 (23.8%)

 
 

EPI-TAM (n = 64)

   
 

   0

40/64 (62.5%)

5/64 (7.8%)

0.00

 

   1

19/64 (29.7%)

25/64 (39.1%)

 
 

   2

5/64 (7.8%)

24/64 (37.5%)

 
 

   3

0.00

10/64 (15.6%)

 
  1. EPI, epirubicin treatment; EPI-TAM, epirubicin plus tamoxifen treatment; PHD, prolyl hydroxylase.